Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

prognostic score

  • Home
  • prognostic score
Allogeneic Stem Cell Transplantation After 70: Japanese Registry Data Define Who May Benefit Most
Posted inHematology-Oncology Internal Medicine news

Allogeneic Stem Cell Transplantation After 70: Japanese Registry Data Define Who May Benefit Most

Posted by MedXY By MedXY 06/19/2026
A Japanese registry study of 929 patients aged 70+ identified six predictors of worse survival after allo-HSCT and created a simple score that sharply stratified 2-year overall survival from 57.1% to 2.5%.
Read More
A New Frontier in Fabry Cardiomyopathy: Validating a T1-Inclusive Prognostic Score for Cardiovascular Risk
Posted inCardiology Nephrology news

A New Frontier in Fabry Cardiomyopathy: Validating a T1-Inclusive Prognostic Score for Cardiovascular Risk

Posted by MedXY By MedXY 01/05/2026
This article explores a novel 3-year prognostic score for Fabry Disease cardiomyopathy, integrating CMR-derived T1 values, LV mass, and LGE extent to predict adverse events, emphasizing the negative predictive value of normal T1 mapping.
Read More
SOFA-2 Recalibrated: Global Development and Validation of an Updated Organ Dysfunction Score in >3.3 Million ICU Admissions
Posted inCritical Care news

SOFA-2 Recalibrated: Global Development and Validation of an Updated Organ Dysfunction Score in >3.3 Million ICU Admissions

Posted by MedXY By MedXY 11/08/2025
SOFA-2 updates the 30-year-old SOFA score using data from >3.3 million ICU admissions across diverse settings. The revised tool modestly improves ICU mortality discrimination (AUROC 0.79 vs 0.77) and incorporates contemporary organ support, with preserved performance over the first ICU week.
Read More
  • Persistent Elevated Risk of Severe COVID-19 Outcomes in Pregnant and Postpartum Individuals Beyond the Pandemic Emergency
  • Unraveling Hepatitis B-Induced Liver Fibrosis: The Critical Role of Pyruvate, PPARα, and Reactive Oxygen Species
  • Unveiling the Role of IL-10-Neutralising Autoantibodies in Pediatric-Onset Inflammatory Bowel Disease: Prevalence, Persistence, and Clinical Implications
  • Decoding Microbial Shifts in Postoperative Crohn’s Disease: Insights into Recurrence Dynamics
  • Perfusion Imaging’s Role in Endovascular Therapy Outcomes for Posterior Cerebral Artery Stroke
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in